Fig. 4: DDI199 treatment deregulates cell cycle and neurotransmission pathways in GSCs.
From: Generation and validation of a novel multitarget small molecule in glioblastoma
A PCA plot of RNAseq and proteomics. B Volcano plot of RNAseq and proteomics based on Fold-change>4 and p-value < 0.01 for RNAseq and p-value < 0.05 for proteomics. C Proportion of DEGs and pathways represented by the biological themes in both OMIC approaches. D Clustering of top 25 Up and Down enriched pathways in combined analysis of RNAseq and proteomics. The width of the connecting bars is indicative of the number of genes that are shared between the two pathways. The full list of pathways is available in Fig. Suppl 6B. E Normal versus tumor expression of common DEGs of the Cell cycle, DNA remodeling and Synapsis clusters in the TCGA cohort. F Correlation analysis of common DEGs from selected clusters with target genes in TCGA cohort. G Expression of common DEGs from selected clusters in glioblastoma cells in a transcriptomic study of SAHA treatment (GEO accession GSE143887) [27]. H q-RTPCR of selected DEGs from each cluster in GNS166 non treated and treated cells (n = 4).
